Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25954086 | 0.94 | LTA4H (0.50) | LTA4HSMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL1011203 | 0.88 | KIF11 (0.45) | LTA4HSMN1; SMN2HTTLMNAKMT2A | |
| Dimethylamine SCHEMBL6491084 | 0.86 | LMNA (0.43) | LTA4HSMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL25954061 | 0.84 | ELANE (0.46) | LTA4HSMN1; SMN2LMNAALDH1A1ACHE | |
| SCHEMBL164160 | 0.84 | ELANE (0.46) | LTA4HSMN1; SMN2LMNAALDH1A1ACHE | |
| SCHEMBL4568634 | 0.83 | PYCR1 (0.41) | SMN1; SMN2HTTLMNAKMT2AMEN1 | |
| SCHEMBL23919140 | 0.83 | LTA4H (0.53) | LTA4HSMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL10102378 | 0.81 | TSHR (0.47) | LTA4HLMNA | |
| SCHEMBL31493151 | 0.79 | KIF11 (0.39) | LTA4HSMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL25954134 | 0.79 | ELANE (0.42) | LTA4HSMN1; SMN2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275418-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| EP-2275418-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | LTA4H 3062/4885SMN1; SMN2 2922/4885HTT 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.